

Martin Koch joins Inotrem as Chief Operating Officer

Paris, January 18th, 2018. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO).

Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining Inotrem, Martin spent 10 years at Genticel, a biotechnology company developing innovative immunotherapies. As Genticel's Chief Financial Officer, Martin was instrumental to the successful growth of the company from the first institutional financing round (2008) to the 2014 IPO on Euronext Paris and Brussels, followed by the merger with GenKyoTex in 2017. Martin Koch brings also to Inotrem a strong international background, having worked in France, Eastern Europe and the UK for top tier companies such as Eli Lilly, Elan Pharmaceuticals and Cephalon.

At Inotrem, Martin will be responsible for supervising the financial activities and secure the business plan's delivery. As part of Inotrem's executive management team, he will actively contribute to the company's strategic development.

Martin Koch, COO, says: *« I am thrilled to join such an experimented team as the one Jean-Jacques Garaud brought together, and participate to Inotrem's promising project. It is a wonderful opportunity to contribute to the development of MOTREM™, the first drug candidate which has the potential to directly act on the immunological mechanism leading to septic shock. With high mortality rates, ranging from 25% to 40%, septic shock is considered by the World Health Organization to be a public health priority ».*

Jean-Jacques Garaud, Inotrem's President, adds: *« We are extremely pleased to welcome Martin as COO. His operational expertise and international background perfectly fit our team. With him on board, Inotrem is ideally positioned to seize growth opportunities, at a pivotal time when the firm's lead compound MOTREM™ is close to complete its first clinical trial in septic shock patients ».*

About Inotrem

Inotrem is a biotechnology company specialized in the control of excessive immune response that occurs in acute inflammatory syndromes in the critical care setting. The Company has developed a new concept of immunomodulation to control abnormal immune response to tissue injuries, using a personalized medicine approach. The Company has been founded in 2013 in Nancy by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. The lead product of Inotrem (MOTREM - LR12) paves the way to new targeted treatments in septic shock and myocardial infarction. The European Medicines Agency (EMA) has granted access to its PRiority MEDicines (PRIME) scheme for its lead product MOTREMTM in the field of septic shock, which is a recognition of both Inotrem's innovative therapeutic approach to the management of acute inflammation and the critical need for causal therapies in a severe condition such as septic shock. Inotrem is supported by leading European specialist investors — Sofinnova Partners, Edmond de Rothschild Investment Partners, Biomed Invest and Inserm Transfert Initiative.

www.inotrem.com

@Inotrem_biotech

Press contact for Inotrem

Anne REIN | S&I | anne.rein@strategiesimage.com | +33 6 03 35 92 05